Business Context and Reporting Period
Company: Fresenius Medical Care AG
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: August 3, 2026
Reporting Period: Second Quarter ended June 30, 2026 (Q2 2026) and First Six Months of 2026.
This filing serves to furnish a Press Release (Exhibit 99.1) and corresponding financial figures (Exhibit 99.2) regarding the Company's Q2 2026 results. The financial results are presented in accordance with International Financial Reporting Standards (IFRS).
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached Exhibits (99.1 and 99.2) which are not included in the provided text.
The Company utilizes the following non-GAAP financial measures to supplement IFRS reporting:
- EBITDA: Operating income excluding interest, taxes, depreciation, and amortization.
- Free Cash Flow.
- Net Leverage Ratio: Ratio of net debt to adjusted EBITDA.
- Constant Currency Results: Adjusted for special items identified in the Press Release.
Reconciliations between these non-GAAP measures and the most comparable IFRS measures are included in the attached Financial Statements.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to Exhibit 99.1 (Press Release) and Exhibit 99.2 (Financial Overview) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The Company states that the inclusion of non-GAAP measures is intended to enhance the user's understanding of current financial performance and future prospects, as well as to provide consistency and comparability with prior periods.
Regulatory Note: The Company explicitly states that non-GAAP measures should not be used as a substitute for or considered superior to GAAP (IFRS) financial measures.
Legal Status of Exhibits: The attached Press Release and financial figures are furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act and are not subject to the liabilities of that section. They are not incorporated by reference in any other filing.
Investor Verification Checklist
- Review Exhibit 99.1 for the full text of the Q2 2026 Press Release to obtain specific revenue and profit figures.
- Examine Exhibit 99.2 for the complete overview of Q2 2026 and the first six months of 2026 financial data.
- Verify the reconciliation tables included in the attached Financial Statements to understand the adjustments made to derive EBITDA, Free Cash Flow, and Net Leverage.
- Confirm the impact of "special items" and currency fluctuations on the reported results as detailed in the Press Release.